A review of NICE appraisals of pharmaceuticals 2000–2016 found variation in establishing comparative clinical effectiveness
Open Access
- 1 January 2019
- journal article
- review article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 105, 50-59
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Strategies To Overcome Hurdles In Hta Appraisals Amid Limitations Resulting From Single-Arm Trial DataValue in Health, 2014
- The Influence of Cost‐Effectiveness and Other Factors on Nice DecisionsHealth Economics, 2014
- Are randomized trials obsolete or more important than ever in the genomic era?Genome Medicine, 2013
- Role of randomized phase III trials in an era of effective targeted therapiesNature Reviews Clinical Oncology, 2011
- Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To ImplementHealth Affairs, 2011
- Pharmacoeconomics: NICE's approach to decision‐makingBritish Journal of Clinical Pharmacology, 2010
- Understanding randomised controlled trialsArchives of Disease in Childhood, 2005
- The Continuing Unethical Conduct of Underpowered Clinical TrialsJAMA, 2002
- For and against: Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial FOR AGAINSTBMJ, 2000
- Users' Guides to the Medical LiteratureJAMA, 1995